Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seattle Gummy Company
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Environmental Hypersensitivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04071821 |
P001-2019 | P1 |
Not yet recruiting |
Environmental Hypersensitivity |
2025-07-15 |
50% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/15/2020 |
News Article |
Seattle Gummy Company Secures The First (IND) Gummy Drug Approval From FDA |